The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

키워드

참고문헌 (110)

1. Mittal D, "New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape", Curr Opin Immunol, 27, pp.16~25 (2014)
2. Chen Daniel S, "Oncology meets immunology : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
3. Gaudino SJ, "Cross-talk between antigen presenting cells and T cells impacts intestinal home-ostasis, bacterial infections, and tumorigenesis", Front Immunol, 10, pp.360~ (2019)
4. Wculek SK, "Dendritic cells in cancer immuno-logy and immunotherapy", Nat Rev Immunol, 20, pp.7~24 (2020)
5. Gardner A, "Dendritic cells and their role in immunotherapy", Front Immunol, 11, pp.924~924 (2020)
6. Hildner K, "Batf3deficiency reveals a critical role for CD8α dendritic cells in cytotoxic T cell immunity", Science, 322, pp.1097~1100 (2008)
7. Sánchez-Paulete AR, "Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells", Cancer Discov, 6, pp.71~79 (2016)
8. Spranger S, "Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy", Cancer Cell, 31, pp.711.e714~723.e714 (2017)
9. Jongbloed SL, "Human CD141+(BDCA-3)+ dendritic cells(DCs)represent a unique myeloid DC subset that cross-presents necrotic cell antigens", J Exp Med, 207, pp.1247~1260 (2010)
10. Broz Miranda L, "Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell im-munity", Cancer Cell, 26, pp.638~652 (2014)
11. Roberts EW, "Critical role for CD103+", CD141+ dendritic cells bearing CCR7for tumor antigen trafficking and priming of T cell immu-nity in melanoma, 2016, pp.30, 324~336
12. Binnewies M, "Un-leashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity", Cell, 177, pp.556.e516~571.e516 (2019)
13. Ferris ST, "cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity", Nature, 584, pp.624~629 (2020)
14. Salmon H, "Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition", Immunity, 44, pp.924~938 (2016)
15. Novak L, "Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication", Mol Cancer Ther, 6, pp.1755~ (2007)
16. Shields JD, "Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21", Science, 328, pp.749~ (2010)
17. Böttcher JP, "The role of type 1conventional dendritic cells in cancer immunity", Trends Cancer, 4, pp.784~792 (2018)
18. Dannull J, "Enhancing the immunostimulatory function of dendritic cells by transfec-tion with mRNA encoding OX40 ligand", Blood, 105, pp.3206~3213 (2005)
19. Buchan SL, "PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell-driven antitumor immunity", Clin Cancer Res, 24, pp.2383~2394 (2018)
20. Martínez-López M, "Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice", Eur J Immunol, 45, pp.119~129 (2015)
21. Ruffell B, "Macrophage IL-10 blocks CD8+ T cell-dependent res-ponses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells", Cancer Cell, 26, pp.623~637 (2014)
22. Chow MT, "Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy", Immunity, 50, pp.1498. e149~1512. e149 (2019)
23. Enamorado M, "Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells", Nature, 8, pp.16073~ (2017)
24. Mittal D, "Interleukin-12from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis", Cancer Immnol, 5, pp.1098~ (2017)
25. Böttcher JP, "NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control", Cell, 172, pp.1022~1037 (2018)
26. Barry KC, "A natural killer-dendritic cell axis defines checkpoint therapy-res-ponsive tumor microenvironments", Nat Med, 24, pp.1178~1191 (2018)
27. Maier B, "A conserved dendritic-cell regulatory program limits antitumour immu-nity", Nature, 580, pp.257~262 (2020)
28. Zong J, "Tumor-derived factors modulating dendritic cell function", Cancer Immnol Immunother, 65, pp.821~833 (2016)
29. Gottfried E, "Tumor-derived lactic acid modulates dendritic cell activa-tion and antigen expression", Blood, 107, pp.2013~2021 (2006)
30. Xu MM, "Dendritic cells but not macrophages sense tumor mitochondrial DNA for crosspriming through signal regulatory protein α signaling", Immunity, 47, pp.363~373 (2017)
31. Villablanca EJ, "Tumormediated liver X receptor- activation inhibits CC che-mokine receptor-7 expression on dendritic cells and dampens antitumor responses", Nat Med, 16, pp.98~105 (2010)
32. Villadangos JA, "Antigen-presentation properties of plasmacytoid dendritic cells", Immunity, 29, pp.352~361 (2008)
33. Zitvogel L, "Type I interferons in anticancer immunity", Nat Rev Immunol, 15, pp.405~414 (2015)
34. Fuertes MB, "Host type I IFN signals are required for antitumor CD8+ T cell res-ponses through CD8+ dendritic cells", J Exp Med, 208, pp.2005~2016 (2011)
35. Diamond MS, "Type I interferon is selectively required by dendritic cells for immune rejection of tumors", J Exp Med, 208, pp.1989~2003 (2011)
36. Zilionis R, "Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species", Immunity, 50, pp.1317~1334 (2019)
37. Aspord C, "Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL", Cancer Immunol Res, 1, pp.402~ (2013)
38. Conrad C, "Plasma-cytoid dendritic cells promote immunosuppression in ovarian cancer via icos costimulation of Foxp3+ T-regu-latory cells", Cancer Res, 72, pp.5240~ (2012)
39. Faget J, "ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the ac-cumulation of immunosuppressive CD4+ T cells", Cancer Res, 72, pp.6130~ (2012)
40. Labidi-Galy SI, "Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis", OncoImmunology, 1, pp.380~382 (2012)
41. Pedroza-Gonzalez A, "Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors", Oncoimmunology, 4, pp.e1008355~e1008355 (2015)
42. Treilleux I, "Dendritic cell infiltration and prognosis of early stage breast cancer", Clin Cancer Res, 10, pp.7466~ (2004)
43. Wei S, "Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma", Cancer Res, 65, pp.5020~ (2005)
44. Sisirak V, "Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells", Int J Cancer, 133, pp.771~778 (2013)
45. Terra M, "Tumor-derived TGFβ alters the ability of plasmacytoid dendritic cells to respond to innate immune signaling", Cancer Res, 78, pp.3014~ (2018)
46. Bruchhage K-L, "IL-10 in the microenvironment of HNSCC inhi-bits the CpG ODN induced IFN-α secretion of pDCs", Oncol Lett, 15, pp.3985~3990 (2018)
47. Bi E, "E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs", J Clin Investig, 128, pp.4821~4831 (2018)
48. Nakano H, "Blood-de-rived inflammatory dendritic cells in lymph nodes sti-mulate acute T helper type 1 immune responses", Nat Immunol, 10, pp.394~402 (2009)
49. Sharma MD, "Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c+ CD103+ monocytic antigen-presenting cells in tumors", Immunity, 48, pp.91~106 (2018)
50. Diao J, "Tumor dendritic cells(DCs)derived from precursors of conventional DCs are dispensable for intratumor CTL responses", J Immunol, 201, pp.1306~ (2018)
51. Qian B-Z, "CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis", Nature, 475, pp.222~225 (2011)
52. Spary LK, "Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer", Oncoimmunology, 3, pp.e955331~ (2014)
53. Laoui D, "The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity", Nat Commun, 7, pp.13720~ (2016)
54. Bakdash G, "Ex-pansion of a BDCA1+ CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines", Cancer Res, 76, pp.4332~ (2016)
55. Deng L, "STING-dependent cytosolic dna sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immuno-genic tumors", Immunity, 41, pp.843~852 (2014)
56. Ghiringhelli F, "Activation of the NLRP3 inflammasome in dendritic cells in-duces IL-1β dependent adaptive immunity against tumors", Nat Med, 15, pp.1170~1178 (2009)
57. Apetoh L, "Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy", Nat Med, 13, pp.1050~1059 (2007)
58. Vacchelli E, "Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1", Science, 350, pp.972~978 (2015)
59. Lecciso M, "ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells", Front Immunol, 8, pp.1918~ (2017)
60. Vanpouille-Box C, "DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity", Nat Commun, 8, pp.15618~ (2017)
61. Hou Y, "Non-canonical NF-κB antagonizes STING sensor-mediated DNA sensing in radiotherapy", Immunity, 49, pp.490~503 (2018)
62. Marigo I, "T cell cancer therapy requires CD40-CD40L activation of tumor ne-crosis factor and inducible nitric-oxide-synthase-produ-cing dendritic cells", Cancer Cell, 30, pp.377~390 (2016)
63. Oba T, "A critical role of CD40 and CD70 signaling in conventional type 1dendritic cells in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells", J Immunol, 205, pp.1867~1877 (2020)
64. Kalbasi A, "Tumour-intrinsic resistance to immune checkpoint blockade", Nat Rev Immunol, 20, pp.25~39 (2020)
65. Mayoux M, "Dendritic cells dictate responses to PD-L1 blockade cancer immuno-therapy", Sci Transl Med, 12, pp.eaav7431~ (2020)
66. Schetters STT, "Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy", J Immunother Cancer, 8, pp.e000588~ (2020)
67. Morrison AH, "Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity", Proc Natl Acad Sci U S A, 117, pp.8022~ (2020)
68. Garris CS, "Success-ful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12", Immunity, 49, pp.1148~1161 (2018)
69. Cauwels A, "Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments", Cancer Res, 78, pp.463~ (2018)
70. Wang H, "cGAS is essential for the antitumor effect of immune checkpoint blockade", Proc Natl Acad Sci U S A, 114, pp.1637~ (2017)
71. Alloatti A, "Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity", J Exp Med, 214, pp.2231~2241 (2017)
72. Nemunaitis J, "Vaccines in cancer : GVAXⓇ, a GM-CSF gene vaccine", Expert Rev Vaccines, 4, pp.259~274 (2005)
73. Yan W-L, "Recent progress in GM-CSF-based cancer immunotherapy", Immunotherapy, 9, pp.347~360 (2017)
74. Bommareddy PK, "Talimogene laherparepvec(T-VEC)and other onco-lytic viruses for the treatment of melanoma", Am J Clin Dermatol, 18, pp.1~15 (2017)
75. Kaufman HL, "Local and distant immu-nity induced by intralesional vaccination with an onco-lytic herpes virus encoding gm-csf in patients with stage IIIc and IV melanoma", Ann Surg Oncol, 17, pp.718~730 (2010)
76. Robinson RA, "A phase I-II trial of multipledose polyriboinosinic-polyribocytidylic acid in patients with leukemia or solid tumors", J Natl Cancer Inst, 57, pp.599~602 (1976)
77. Kyi C, "Therapeutic immune modulation against solid cancers with intratu-moral poly-ICLC : a pilot trial", Clin Cancer Res, 24, pp.4937~4948 (2018)
78. Navabi H, "A clinical grade poly I : C-analogue(AmpligenⓇ)promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro", Vaccine, 27, pp.107~115 (2009)
79. Aznar MA, "Immunotherapeutic effects of intratumoral nanoplexed poly I : C", J Immunother Cancer, 7, pp.116~ (2019)
80. Corrales L, "Direct activation of sting in the tumor microenvironment leads to potent and systemic tumor regression and immunity", Cell Rep, 11, pp.1018~1030 (2015)
81. Finn OJ, "Human tumor antigens yesterday, today, and tomorrow", Cancer Immunol Res, 5, pp.347~ (2017)
82. Harari A, "Antitumour dendritic cell vaccination in a priming and boosting approach", Nat Rev Drug Discov, 19, pp.635~652 (2020)
83. Gleisner MA, "A heatshocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth", J Immunother Cancer, 8, pp.e000999~ (2020)
84. Callmann CE, "Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer", Proc Natl Acad Sci U S A, 117, pp.17543~ (2020)
85. Yarchoan M, "Targeting neoantigens to augment antitumour immunity", Nat Rev Cancer, 17, pp.209~222 (2017)
86. Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
87. Balachandran VP, "Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer", Nature, 551, pp.512~516 (2017)
88. Ott PA, "An immunogenic personal neoantigen vaccine for patients with melano-ma", Nature, 547, pp.217~221 (2017)
89. Keskin DB, "Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial", Nature, 565, pp.234~239 (2019)
90. Kim JH, "Phase I", II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma, 2007, pp.125, 257~267
91. Powell A, "Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothe-lioma", Lung Cancer, 52, pp.189~197 (2006)
92. Tsuji T, "Antibodytargeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell respon-ses with broad antigen specificity", J Immunol, 186, pp.1218~ (2011)
93. Birkholz K, "Tar-geting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation", Blood, 116, pp.2277~2285 (2010)
94. Anguille S, "Clinical use of dendritic cells for cancer therapy", Lancet Oncol, 15, pp.e257~e267 (2014)
95. Draube A, "Dendritic cell based tumor vaccination in prostate and renal cell cancer : a systematic review and meta-analysis", PLoS One, 6, pp.e18801~ (2011)
96. Kantoff PW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
97. Mastelic-Gavillet B, "Personalized dendritic cell vaccines—recent breakthroughs and encouraging clinical results", Front Immunol, 10, pp.766~ (2019)
98. van Willigen WW, "Dendritic cell cancer therapy : vaccinating the right patient at the right time", Front Immunol, 9, pp.2265~ (2018)
99. Carreno BM, "A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells", Science, 348, pp.803~ (2015)
100. Perez CR, "Engineering dendritic cell vaccines to improve cancer immunotherapy", Nat Commun, 10, pp.5408~ (2019)
101. Okada N, "Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction", Gene Ther, 12, pp.129~139 (2005)
102. Yang X, "Immune adjuvant targeting micelles allow efficient dendritic cell mig-ration to lymph nodes for enhanced cellular immunity", ACS Appl Mater Interfaces, 10, pp.33532~33544 (2018)
103. Wang J, "microRNA-155deficiency impairs dendritic cell function in breast cancer", Oncoimmunology, 5, pp.e1232223~ (2016)
104. Lind EF, "miR-155upregulation in dendritic cells is sufficient to break tolerance in vivo by negatively regulating SHIP1", J Immunol, 195, pp.4632~ (2015)
105. Wilgenhof S, "Phase II study of autologous monocyte-derived mrna electroporated dendritic cells(TriMixDC-MEL)plus ipilimumab in patients with pretreated advanced melanoma", J Clin Oncol, 34, pp.1330~1338 (2016)
106. Yang S-C, "Intratumoral administration of dendritic cells overexpressing CCL21generates systemic antitumor responses and confers tumor immunity", Clin Cancer Res, 10, pp.2891~ (2004)
107. Lee JM, "Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration", Clin Cancer Res, 23, pp.4556~4568 (2017)
108. Wculek SK, "Effective cancer immunotherapy by natural mouse conventional type-1dendritic cells bearing dead tumor antigen", J Immunother Cancer, 7, pp.100~ (2019)
109. Kadam P, "PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer", Vaccines, 8, pp.317~ (2020)
110. Teng C-F, "Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model", Ther Adv Med Oncol, 12, pp.1758835920922034~ (2020)

관련 논문AI추천